AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase follows an announcement of a collaboration agreement between AKESO and INOVIO. The partnership will involve cooperation with Dana Farber Cancer Institute, a world-leading cancer research organization, and Mass General Brigham, a top-tier healthcare group, to jointly explore innovative treatments for glioblastoma (GBM). The research will focus on combining AKESO's globally first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, with INOVIO's DNA-based therapeutic INO-5412. Dr. Xia Yu, Founder, Chairman, President, and CEO of AKESO, stated that cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy. She emphasized that AKESO is accelerating the global development of cadonilimab through a diversified strategy of in-house development and international collaboration. The company aims to fully explore the groundbreaking clinical value and international potential of cadonilimab as a cornerstone agent for combination immunotherapy, thereby advancing cancer immunotherapy into its next phase of development.